In a pivotal development, the FDA has announced that Tirzepatide is officially off the shortage list. This decision marks the beginning of a 60-day transition period, allowing compounding pharmacies to continue producing Tirzepatide until February 19, 2025.

While this update suggests some improvement in the availability of FDA-approved Tirzepatide, the situation remains complex. Many pharmacies are still reporting insufficient supplies from wholesalers, and the Alliance for Pharmacy Compounding (APC) has emphasized that this announcement does not fully address the challenges facing patients and providers. Moreover, with litigation still ongoing, the long-term availability of compounded Tirzepatide remains uncertain.

At Regenics, we recognize the significance of this transition period and are taking decisive action to ensure uninterrupted care for our patients. Our team is actively coordinating with trusted pharmacy partners and monitoring the evolving situation to minimize any potential impact on your treatment.

This is a critical moment for patients relying on Tirzepatide. We encourage anyone considering starting or adjusting their treatment to act promptly, as access beyond the transition period is unclear.

Your health remains our top priority, and we are committed to keeping you informed every step of the way.